Like any other tool, understanding the right problem to apply it to is the difference between success and failure. Addressing a problem is never just about technology; it’s always about people, processes, and technology.
As RNA biology and RNA therapeutics emerge in the mainstream of pharma, RNA foundation models offer massive potential for revolutionizing R&D.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The ability to take a drug to market is an important milestone, but it is not the entire picture. To truly move the needle, both clinically and commercially, biopharma companies must fine-tune their teams, approaches and incentives to produce unique and innovative products.
It is critical that we rightsize and redistribute available funds based on our knowledge of persistent cancer disparities to help more patients benefit from potentially lifesaving innovations and ensure no one is left behind.
R&D spending rose in response to Covid-19, bringing with it higher expectations for returns on all biopharma investments. The once sky-high projections are coming down to Earth, with returns now in line with pre-pandemic levels, according to a new Deloitte report.
Johnson & Johnson's CEO believes the company will maintain its strong reputation for innovation amid changing economic conditions because of its hefty investments in research and development. He said it's crucial to invest both internally and externally, as some of the most innovative and lucrative opportunities come from outside companies.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
The model of investing huge amounts of money into one drug to try to recoup it later is problematic at best and unsustainable at worst. Platform technology provides a better, more cost-effective way forward.
This panel explores some of the diverse approaches companies are taking to improve efficiency and avert pitfalls in therapeutic development.
The conference, set for June 9-11, will explore different aspects of precision medicine, including the software being used to support drug and therapeutic development.
Cho discusses Bristol Myers Squibb’s research efforts in the field of protein degradation to advance potential treatments for a broad range of diseases. In a recent MedCity Pivot Podcast, he also shared insights on his approach to drug discovery, perspectives on dealing with failure, and some of the work his teams are doing in the COVID-19 space.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
We live in a golden age of medicine. Never before have so many effective treatment options been available to so many people. And precision medicine is bringing new horizons, as well as the promise to further improve disease prevention, treatment, and ultimately find more cures. To keep moving toward personalized medicine approaches, more individuals would […]